Clinical Trial Update: Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing intravenous and subcutaneous administration of 10% intravenous immunoglobulin for primary immunodeficiency diseases has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• IGIV 10%

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-08-23